Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Abstract Background PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-066...

Description complète

Détails bibliographiques
Auteurs principaux: Spencer I. Danto, Negin Shojaee, Ravi Shankar P. Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan, Iain Kilty
Format: Article
Langue:English
Publié: BMC 2019-12-01
Collection:Arthritis Research & Therapy
Sujets:
IRAK4
Pharmacokinetic
Pharmacodynamic
Accès en ligne:https://doi.org/10.1186/s13075-019-2008-6

Internet

https://doi.org/10.1186/s13075-019-2008-6

Documents similaires